SZSong Zhao

Song Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Song Zhao has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tertiary syphilis in the lumbar spine: a case report

    by Yang Bai, Feng Niu, Lidi Liu, Hui Sha, Yimei Wang, Song Zhao

    The incidence of tertiary syphilis involvement in the spinal column with destructive bone lesions is very rare. It is difficult to establish the correct diagnosis from radiographs and histological examination alone. Limited data are available on surgical treatment to tertiary syphilitic spinal lesions. In this article, we report a case of tertiary syphilis in the lumbar spine with osteolytic lesions causing cauda equina compression. A 44-year-old man who suffered with low back pain for 6 months and progressive radiating pain at lower extremity for 1 week. Radiologic findings showed osteolytic lesion and new bone formation in the parts of the bodies of L4 and L5. Serum treponema pallidum hemagglutination (TPHA) test was positive. A surgery of posterior debridement, interbody and posterolateral allograft bone fusion with instrumentation from L3 to S1 was performed. The low back pain and numbness abated after operation. But the follow-up radiographs showed absorption of the bone grafts and failure of instrumentation. A Charcot’s arthropathy was formed between L4 and L5. It is challenging to diagnose the tertiary syphilis in the spine. Surgery is a reasonable auxiliary method to antibiotic therapy for patients who suffered with neuropathy. Charcot’s arthropathy should be considered as an operative complication.


  • Open Access

    Sulforaphane protection against the development of doxorubicin‐induced chronic heart failure is associated with Nrf2 Upregulation

    by Yang Bai, Qiang Chen, Yun‐Peng Sun, Xuan Wang, Li Lv, Li‐Ping Zhang, Jin‐Sha Liu, Song Zhao, Xiao‐Lu Wang

    Summary: Background: Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose‐dependent cardiotoxicity and even progresses to chronic heart failure (CHF).Objective: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX‐induced CHF.Methods: Male Sprague‐Dawley rats which received treatment for 6 weeks were divided into four groups (n=30 per group): control, SFN, DOX and DOX plus SFN group.Results: Results revealed that DOX induced progressive cardiac damage as indicated by increased cardiac injury markers, cardiac inflammation, fibrosis and oxidative stress. SFN significantly prevented DOX‐induced progressive cardiac dysfunction between 2‐6 weeks and prevented DOX‐induced cardiac function deterioration. Furthermore, it significantly decreased ejection fraction and increased the expression of brain natriuretic peptide. SFN also almost completely prevented DOX‐induced cardiac oxidative stress, inflammation and fibrosis. SFN upregulated NF‐E2‐related factor 2 (Nrf2) expression and transcription activity, which was reflected by the increased mRNA expression of Nrf2 and its downstream genes. Furthermore, in cultured H9c2 cardiomyocytes, the protective effect of SFN against DOX‐induced fibrotic and inflammatory responses was abolished by Nrf2 silencing.Conclusion: We arrived at the conclusion that DOX‐induced CHF can be prevented by SFN through the upregulation of Nrf2 expression and transcriptional function.